Pharmacogenetics of adverse events in schizophrenia treatment: comparison study of ziprasidone, olanzapine and perazine.

Abstract

The primary aim of the present study was to assess the possible associations between dopaminergic, serotonergic, and glutamatergic system-related genes and adverse events after antipsychotic treatment in paranoid schizophrenia patients. The second aim of the study was to compare the intensity of these symptoms between atypical (ziprasidone and olanzapine) and typical (perazine) antipsychotic drugs. One-hundred and ninety-one Polish patients suffering from paranoid schizophrenia were genotyped for polymorphisms of DRD2, DAT1, COMT, MAOA, SERT, 5HT2A, and GRIK3. The patients were randomized to treatment with perazine, olanzapine or ziprasidone monotherapy for 3 months. The intensity of side effects (changes in body weights and extrapyramidal symptoms (EPS)) was measured at baseline and after 12 weeks of antipsychotic treatment. After 3 months of therapy, the weight increase was the greatest in the group treated with olanzapine and the least in the group treated with ziprasidone. None of the examined gene polymorphisms was associated with the body weight changes. Perazine treatment was associated with the significantly highest intensity of EPS. None of the examined polymorphisms was associated with the changes in extrapyramidal adverse events after antipsychotic treatment. The selected polymorphisms are not primarily involved in changes in body weights and EPS related to antipsychotic treatment in paranoid schizophrenia patients.

• Authors: Piotr Tybura, Beata Trześniowska-Drukała, Przemyslaw Bienkowski, Aleksander Beszlej, Dorota Frydecka, Pawel Mierzejewski, Agnieszka Samochowiec, Anna Grzywacz, Jerzy Samochowiec
• Journal: Psychiatry research (Psychiatry Res) Vol. 219 Issue 2 Pg. 261-7 (Oct 30 2014) ISSN: 1872-7123 [Electronic] Ireland
• PMID: 24930580 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Chemical References

• Antipsychotic Agents
• DRD2 protein, human
• Dopamine Plasma Membrane Transport Proteins
• Piperazines
• Receptor, Serotonin, 5-HT2A
• Receptors, Dopamine D2
• Receptors, Kainic Acid
• SLC6A3 protein, human
• SLC6A4 protein, human
• Serotonin Plasma Membrane Transport Proteins
• Thiazoles
• Benzodiazepines
• ziprasidone
• Perazine
• Monoamine Oxidase
• COMT protein, human
• Catechol O-Methyltransferase
• Olanzapine

Topics

• Adult
• Antipsychotic Agents (adverse effects, therapeutic use)
• Basal Ganglia Diseases (chemically induced, genetics)
• Benzodiazepines (adverse effects, therapeutic use)
• Catechol O-Methyltransferase (genetics)
• Dopamine Plasma Membrane Transport Proteins (genetics)
• Female
• Genotype
• Humans
• Male
• Middle Aged
• Monoamine Oxidase (genetics)
• Olanzapine
• Overweight (chemically induced, genetics)
• Perazine (adverse effects, therapeutic use)
• Piperazines (adverse effects, therapeutic use)
• Polymorphism, Genetic
• Receptor, Serotonin, 5-HT2A (genetics)
• Receptors, Dopamine D2 (genetics)
• Receptors, Kainic Acid (genetics)
• Schizophrenia, Paranoid (drug therapy, genetics)
• Serotonin Plasma Membrane Transport Proteins (genetics)
• Thiazoles (adverse effects, therapeutic use)
• Weight Gain (drug effects, genetics)
• Young Adult
• GluK3 Kainate Receptor